Human retroviral infections: immunological and therapeutic control
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
New York [u.a.]
Kluwer Acad./Plenum
2000
|
| Schriftenreihe: | Infectious agents and pathogenesis
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XXII, 368 S. Ill., graph. Darst. |
| ISBN: | 0306462222 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV013495358 | ||
| 003 | DE-604 | ||
| 005 | 20021203 | ||
| 007 | t | ||
| 008 | 001214s2000 ad|| |||| 00||| eng d | ||
| 020 | |a 0306462222 |9 0-306-46222-2 | ||
| 035 | |a (OCoLC)44533847 | ||
| 035 | |a (DE-599)BVBBV013495358 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 050 | 0 | |a QR201.R47 | |
| 082 | 0 | |a 616.9/25 |2 21 | |
| 084 | |a YD 8400 |0 (DE-625)153349:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Human retroviral infections |b immunological and therapeutic control |c ed. by Kenneth E. Ugen ... |
| 264 | 1 | |a New York [u.a.] |b Kluwer Acad./Plenum |c 2000 | |
| 300 | |a XXII, 368 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a Infectious agents and pathogenesis | |
| 650 | 4 | |a HIV Infections |x immunology | |
| 650 | 4 | |a HIV Infections |x therapy | |
| 650 | 4 | |a Retrovirus infections | |
| 650 | 0 | 7 | |a Retroviren-Infektion |0 (DE-588)4209311-9 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Retroviren-Infektion |0 (DE-588)4209311-9 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Ugen, Kenneth E. |e Sonstige |4 oth | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009211332&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-009211332 | ||
Datensatz im Suchindex
| _version_ | 1804128285709303808 |
|---|---|
| adam_text | Contents
1. The Two Principal Viremias of HIV: A Comparison of Viral
and Host Characteristics 1
CYNTHIA L. BRISTOW
1. Introduction 1
2. Sexual Transmission 3
2.1. The Infectious Unit 3
2.2. The Target Cell 3
2.3. The Environment 4
3. Autologous Transmission 7
3.1. The Infectious Unit 7
3.2. The Target Cell 8
3.3. The Environment 9
4. Conclusions 11
References 11
2. Potential Role of Human T Cell Leukemia/Lymphoma Viruses
(HTLV) in Diseases Other Than Acute T Cell Leukemia/
Lymphoma (ATL) 17
TERESA C. GENTILE and THOMAS P. LOUGHRAN
1. Introduction 17
2. Neurologic Disease 18
3. Hematologic Disease 20
4. Autoimmune/Inflammatory 22
5. Dermatologic Disease 23
XV
xvi CONTENTS
6. Other Reported Disease Associations 24
References 24
3. Viral Related Proteins in Immune Dysfunction Associated
with AIDS 29
GEORGE J. CIANCIOLO
1. Immunologic Dysfunction Associated with HIV Infection . . 31
2. Reported Effects of HIV 1 Tat on Immune Cell Function .. 31
3. Reported Effects of HIV 1 gpl20 on Immune Cell Function 35
4. Reported Effects of HIV 1 gp41 on Immune Cell Function 41
5. Reported Effects of HIV 1 Nef on Immune Cell Function . . 44
6. Summary 53
References 53
4. Carbohydrate Interactions and HIV 1 61
THOMAS KIEBER EMMONS
1. Introduction 61
2. Carbohydrate Structures Are Ubiquitous in Nature 63
3. Influence of Carbohydrate Moieties on the Immunogenicity
of HIV 67
4. Role of Carbohydrate in Vaccine Strategies to HIV 72
5. Mucosal Immune Responses 78
6. Summary 79
References 80
5. HTLV I and HTLV II Infection: Immunological and Molecular
Aspects 87
MOSI K. BENNETT and MICHAEL G. AGADJANYAN
1. Introduction 87
2. Biology of HTLV 88
3. HTLV Vaccine Development 91
4. Receptors for HTLV 93
5. Adhesion Molecules and HTLV Infection 95
References 103
CONTENTS xvii
6. Vaccine Approaches for Human T Cell Lymphotropic Virus
Type I 109
G. A. DEKABAN, A. PETERS, J. ARP, and G. FRANCHINI
1. Introduction 109
2. Issues Relevant to HTLV I Vaccine Development Ill
2.1. HTLV I Tropism Ill
2.2. The Natural Immune Response to HTLV I Infection .. 112
2.3. Feasibility of Generating an HTLV I Vaccine 112
2.4. Genetic Stability 112
3. Available Animal Models 113
3.1. Rodent Models 113
3.2. Nonhuman Primate Models 115
4. Modes of Challenge 116
5. Vaccine Approaches Relevant to HTLV I 117
5.1. Inactivated and Live Attenuated Viruses 117
5.2. Subunit Approach 118
5.3. Live Vectors 118
5.4. Immunization by DNA Gene Transfer 119
6. HTLV I Vaccine Candidates 120
6.1. Tax 121
6.2. Pol and pX Region Proteins 121
6.3. Envelope Glycoprotein 122
6.4. Gag 123
6.5. Polyvalent Vaccine 124
7. HTLV I Animal Vaccine Challenge Studies 125
7.1. Rat Vaccine Studies 125
7.2. Rabbit Vaccine Studies 126
7.3. Nonhuman Primate Vaccine Studies 129
8. Summary 129
References 131
7. Immune Responses against HFV 2 143
EWA BJORLING
1. Introduction 143
2. Properties of Different HrV 2 Proteins 144
3. Immune Responses against HIV 2 144
3.1. Humoral Immunity 145
3.2. Antibody Dependent Cellular Cytotoxicity 151
xviii CONTENTS
3.3. Cell Mediated Immunity 153
4. Conclusion 156
References 157
8. HIV Mucosal Vaccines 165
HERMAN F. STAATS and JERRY R. McGHEE
1. Introduction 165
2. HIV Infection at Mucosal Surfaces 166
3. Correlates of Protection for Mucosally Transmitted HIV ... 168
3.1. HIV Exposed but Uninfected 168
3.2. Mucosal SIV Challenge in Nonhuman Primates 170
4. Mucosal HIV Vaccine Needed 170
4.1. Organization of the Mucosal Immune System 171
4.2. Mucosal Antibody Responses: Secretory IgA 172
4.3. Mucosal Cell Mediated Immunity: Cytotoxic T
Lymphocytes 174
4.4. Routes of Immunization for the Induction of Anti HIV
Mucosal Immune Responses 174
5. Mucosal HIV Vaccine Strategies 175
5.1. Protein Subunits 175
5.2. Peptide Vaccines 177
5.3. Virus like Particles 178
5.4. Recombinant Viral Vectors 179
5.5. Recombinant Bacterial Vectors 179
5.6. DNA Vaccines 180
5.7. Live Attenuated SIV 180
6. Mucosal Adjuvants 181
7. Conclusions 181
References 182
9. Nucleic Acid Vaccination against HFV 1 191
AMI R. SHAH, DAVID B. WEINER, and JEAN D. BOYER
1. Introduction 191
2. Obstacles to HIV 1 Vaccine Development 192
2.1. Introduction 192
2.2. Immune Responses to HIV 1 and Potential Correlates
of Protection 194
CONTENTS xix
3. The Genome of HIV 1 and Targets for Nucleic Acid
Vaccination 196
4. DNA Based Vaccines 199
5. Progress of Nucleic Acid Immunization against HIV 1 200
5.1. Murine Studies 200
5.2. Primate Studies 206
5.3. Human Studies 208
6. Conclusion 210
References 210
10. Passive Immunotherapy against HIV 1: Current Status and
Potential 217
JOSEPH P. COTROPIA and KENNETH E. UGEN
1. Introduction 217
2. Humoral Immune Responses against HIV 1 218
3. Humoral Immune Responses against gpl20 219
4. Humoral Immune Responses against gp41 219
5. Convergent/Synergistic Passive Immunotherapy 222
6. Evidence for Protective Efficacy of Humoral Immunity
against HIV 1 223
7. Passive Immunotherapy Trials of Clinical Relevance
Utilizing HFV Immune Serum Globulin 224
8. Monoclonal Antibodies Utilized in Passive Immunotherapy 225
8.1. Chimpanzee Model 225
8.2. Human Trials 227
8.3. hu PBL SCID Mouse Model 229
9. Summary 230
References 232
11. Human Immunodeficiency Virus Type 1 Accessory Genes:
Targets for Therapy 239
SAGAR KUDCHODKAR, T. NAGASHUNMUGAM,
and VELPANDI AYYAVOO
1. Introduction 239
2. Vif 242
2.1. Structure and Function 242
2.2. Vaccine and Drug Studies 245
xx CONTENTS
3. Vpu 247
3.1. Structure and Function 247
3.2. Vaccine and Drug Studies 249
4. Nef 250
4.1. Structure and Function 250
4.2. Vaccine and Drug Studies 252
5. Vpr 253
5.1. Structure and Function 253
5.2. Vaccine and Drug Studies 255
6. Conclusion 257
References 257
12. A New Generation of Antiviral Therapeutics Designed to
Prevent the Use of Chemokine Receptors for Entry by HIV 1 269
BENJAMIN J. DORANZ and ROBERT W. DOMS
1. Introduction 269
2. Chemokine Receptors as HIV 1 Coreceptors 270
3. Chemokine Receptors as Pathogenic Determinants 272
4. Chemokine Inhibition of HIV 1 273
5. Therapeutics Directed at Chemokine Receptors 274
6. Small Molecule Inhibitors of Chemokine Receptors 276
7. Future Directions 279
References 279
13. Protease Inhibitors and HIV 1 Genetic Variability in Infected
Children 287
MAUREEN M. GOODENOW, ELENA E. PEREZ,
and JOHN W. SLEASMAN
1. Antiviral Drug Therapies 287
1.1. Introduction 287
1.2. HIV 1 Targets for Drugs 288
1.3. HIV 1 Protease 288
1.4. Viral Drug Resistance 289
2. Antiviral Drugs and Pediatric Patients 291
2.1. Drugs for HIV 1 Infected Children 291
2.2. Protease Inhibitors and Clinical Response 292
CONTENTS xxi
2.3. Immune Reconstitution Following PR Inhibitor
Therapy in Children 294
3. Genetic Analysis of Protease in Response to Protease
Inhibitors 295
3.1. Patients 295
3.2. Methods 295
3.3. Phylogenetic Trees 296
3.4. Genotypic Resistance in Protease 297
3.5. Genetic Distance in Protease over Time 298
3.6. Models for Evolution of Virus with Inhibitor 298
4. Virus from Other Perspectives 300
4.1. Variability in env Region of the Virus Genome 300
4.2. Genetic Analysis and Reservoirs of Viruses 303
References 303
14. Gene Therapy and HTV 1 Infection: Experimental Approaches,
Shortcomings, and Possible Solutions 307
RALPH DORNBURG and ROGER POMERANTZ
1. HIV 1 Infection and Conventional Pharmaceutical Agents 307
2. Antisense RNAs and Ribozymes 308
3. RNA Decoys 310
4. Transdominant Mutant Proteins 310
5. Toxic Genes 311
6. CD4 as Decoy 312
7. Single Chain Antibodies 312
8. Gene Delivery of Antiviral Agents 312
9. Other New Potential Vector Systems 316
10. Other Potential Problems 317
References 318
15. Pediatric HIV: Antiretroviral Therapy 325
ROBERT P. NELSON, JR., PATRICIA J. EMMANUEL,
and MATTE DE LA MORENA
1. Introduction 325
2. Antiretroviral Agents 331
2.1. Nucleoside Analogue Reverse Transcriptase Inhibitors 331
xxii CONTENTS
2.2. Nonnucleoside Reverse Transcriptase Inhibitors 334
2.3. Protease Inhibitors 335
2.4. Nucleotide Reverse Transcriptase Inhibitor 337
3. Pediatric Antiretroviral Treatment 337
3.1. Identification of Perinatal HIV Exposure 337
3.2. HIV Diagnosis in Infants 338
3.3. Immunological Monitoring in Children 338
3.4. Monitoring HIV RNA in Children 339
3.5. Initiation of Antiretroviral Therapy 340
3.6. Choice of Initial Antiretroviral Therapy 341
3.7. Changes in Antiretroviral Therapy 341
3.8. Duration of Therapy 342
3.9. Salvage Antiretroviral Therapy 343
Appendix 344
References 354
Index 357
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV013495358 |
| callnumber-first | Q - Science |
| callnumber-label | QR201 |
| callnumber-raw | QR201.R47 |
| callnumber-search | QR201.R47 |
| callnumber-sort | QR 3201 R47 |
| callnumber-subject | QR - Microbiology |
| classification_rvk | YD 8400 |
| ctrlnum | (OCoLC)44533847 (DE-599)BVBBV013495358 |
| dewey-full | 616.9/25 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.9/25 |
| dewey-search | 616.9/25 |
| dewey-sort | 3616.9 225 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01444nam a2200385 c 4500</leader><controlfield tag="001">BV013495358</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20021203 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">001214s2000 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0306462222</subfield><subfield code="9">0-306-46222-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)44533847</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV013495358</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QR201.R47</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.9/25</subfield><subfield code="2">21</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YD 8400</subfield><subfield code="0">(DE-625)153349:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Human retroviral infections</subfield><subfield code="b">immunological and therapeutic control</subfield><subfield code="c">ed. by Kenneth E. Ugen ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York [u.a.]</subfield><subfield code="b">Kluwer Acad./Plenum</subfield><subfield code="c">2000</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXII, 368 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Infectious agents and pathogenesis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HIV Infections</subfield><subfield code="x">immunology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HIV Infections</subfield><subfield code="x">therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Retrovirus infections</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Retroviren-Infektion</subfield><subfield code="0">(DE-588)4209311-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Retroviren-Infektion</subfield><subfield code="0">(DE-588)4209311-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ugen, Kenneth E.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009211332&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-009211332</subfield></datafield></record></collection> |
| id | DE-604.BV013495358 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T18:46:49Z |
| institution | BVB |
| isbn | 0306462222 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-009211332 |
| oclc_num | 44533847 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | XXII, 368 S. Ill., graph. Darst. |
| publishDate | 2000 |
| publishDateSearch | 2000 |
| publishDateSort | 2000 |
| publisher | Kluwer Acad./Plenum |
| record_format | marc |
| series2 | Infectious agents and pathogenesis |
| spelling | Human retroviral infections immunological and therapeutic control ed. by Kenneth E. Ugen ... New York [u.a.] Kluwer Acad./Plenum 2000 XXII, 368 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Infectious agents and pathogenesis HIV Infections immunology HIV Infections therapy Retrovirus infections Retroviren-Infektion (DE-588)4209311-9 gnd rswk-swf Retroviren-Infektion (DE-588)4209311-9 s DE-604 Ugen, Kenneth E. Sonstige oth HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009211332&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Human retroviral infections immunological and therapeutic control HIV Infections immunology HIV Infections therapy Retrovirus infections Retroviren-Infektion (DE-588)4209311-9 gnd |
| subject_GND | (DE-588)4209311-9 |
| title | Human retroviral infections immunological and therapeutic control |
| title_auth | Human retroviral infections immunological and therapeutic control |
| title_exact_search | Human retroviral infections immunological and therapeutic control |
| title_full | Human retroviral infections immunological and therapeutic control ed. by Kenneth E. Ugen ... |
| title_fullStr | Human retroviral infections immunological and therapeutic control ed. by Kenneth E. Ugen ... |
| title_full_unstemmed | Human retroviral infections immunological and therapeutic control ed. by Kenneth E. Ugen ... |
| title_short | Human retroviral infections |
| title_sort | human retroviral infections immunological and therapeutic control |
| title_sub | immunological and therapeutic control |
| topic | HIV Infections immunology HIV Infections therapy Retrovirus infections Retroviren-Infektion (DE-588)4209311-9 gnd |
| topic_facet | HIV Infections immunology HIV Infections therapy Retrovirus infections Retroviren-Infektion |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009211332&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT ugenkennethe humanretroviralinfectionsimmunologicalandtherapeuticcontrol |